Consumers who filled a generic prescription made by one of five drug companies between 2009 and 2019 need to register before any settlement money moves, and that step is not the same as filing a claim. The distinction matters because a $29.6 million settlement with generic drug maker Glenmark cleared preliminary court approval on August 7, 2026, but the claim process that would actually send money to individual households has not opened yet. Because the covered window runs more than a decade across five manufacturers, the eligible group is far larger than what a typical single-product recall would touch.
Which Purchases Are Covered
The purchase window runs from May 2009 through December 2019, and it applies to generic prescription drugs made by any of five companies: Glenmark, Lannett, Bausch, Apotex or Heritage. Each of the five reached its own settlement with the same coalition of state attorneys general after a years-long investigation into whether generic manufacturers coordinated prices instead of competing for business, according to the Pennsylvania Attorney General’s office.
Because the covered period spans more than a decade and touches five separate manufacturers, the number of people who could qualify is large and not limited to any single medication or diagnosis. A consumer does not need to know which specific drug they took or remember the exact pharmacy that filled it; the eligibility check run through the settlement program is built to sort that out using records the manufacturers and pharmacy benefit systems can match. Consumers who kept old pharmacy printouts, prescription receipts or insurance explanation-of-benefits statements from that decade may find them useful later, even though none of that paperwork is required just to register.
Free retirement updates: Keep more of your Social Security and savings with plain-English updates on the changes, deadlines, and costly mistakes retirees miss. Subscribe free.
Registering Is Not the Same as Filing a Claim
To check eligibility, consumers can call 1-866-290-0182, email info@AGGenericDrugs.com or visit AGGenericDrugs.com. That registration step confirms whether a person falls within the covered purchase window, but it does not put money in anyone’s hands. The actual claim form for the Glenmark portion of the settlement has not been released, and a payment schedule cannot be set until the settlement receives final court approval on top of the preliminary approval already granted.
Because the claim process is still pending, anyone who receives an unsolicited call, text or email demanding payment or banking information to “process” a Glenmark claim right now is not dealing with the official settlement program. Registering through the phone number, email or website listed by the state attorneys general costs nothing and does not require sharing financial account numbers.
A Separate, Already-Open Claim Window Covers the Same Years
Consumers researching the Glenmark registration may also come across a second, unrelated settlement program tied to the same May 2009 to December 2019 purchase window. That program, run through federal class-action counsel rather than the state attorneys general, is accepting claim forms right now at GenericDrugsEndPayerSettlement.com for settlements already reached with different generic manufacturers — Sandoz, Fougera, Sun Pharmaceutical and Taro Pharmaceuticals — with a filing deadline of November 9, 2026. That federal track does not include Glenmark, Lannett, Bausch, Apotex or Heritage, which remain part of the state program described above.
The two tracks exist because state attorneys general and private class-action lawyers pursued separate lawsuits over the same underlying industry-wide price-fixing allegations, in different courts, against different combinations of manufacturers. Registering with the state attorneys general does not automatically enter anyone into the federal claims process, and filing a claim in the federal case does not register a person for the Glenmark money. Consumers who bought generic prescriptions during that decade, and who paid out of pocket or through an insurance copay, may want to look into both programs, since qualifying for one does not rule out qualifying for the other.
How the Money Gets Divided Among States
Once the fund is finalized, the $29.6 million doesn’t move as a single national pool paid out person by person. It splits first among the participating states and territories based on formulas tied to each state’s population and estimated share of affected purchases, and each state then runs its own process for reaching residents. Vermont, for example, is set to receive $66,811 of the total as its share of the settlement, according to the Vermont Attorney General’s office — a small fraction of the overall settlement that shows how thinly a nationwide dollar figure can spread once it reaches individual states.
That state-by-state breakdown is also why the timeline for opening claims may not be identical everywhere; some states may issue consumer notices and set up claim portals sooner than others even though the underlying settlement terms are the same nationwide. Consumers who register now through the national AGGenericDrugs.com program will be positioned to hear about their own state’s next steps as soon as a claim form is ready, without needing to track each state’s announcement separately.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- Adding someone to your bank account: tax traps and smart moves
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
